Molecular Virology and the Development of Resistant Mutants: Implications for Therapy

ABSTRACT

Two of the key events in the viral life cycle of the hepatitis B virus (HBV) involve (1) generation from genomic DNA of the covalently closed circular DNA transcriptional template and (2) reverse transcription of the viral pregenomic RNA to form the HBV DNA genome. Because the virus employs reverse transcription to copy its genome, mutant viral genomes are found frequently. Particular selection pressures, both endogenous (host immune clearance) and exogenous (vaccines and antivirals), readily select out these escape mutants. The introduction of nucleoside/nucleotide analogue therapy has seen the emergence of drug resistance as the major factor limiting drug efficacy. The development of drug resistance is not unexpected if viral replication continues in the setting of ongoing treatment, especially monotherapy. Thus, prevention of resistance requires the adoption of strategies that effectively control virus replication.

Reverse transcription - covalently closed circular DNA - viral mutants - drug resistance - vaccine escape

REFERENCES

• 1 Chisari F, Ferrari C. Hepatitis B virus immunopathogenesis.  Annu Rev Immunol. 1995;  13 29-60
• 2 Norder H, Courouce A M, Magnius L O. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes.  Virology. 1994;  198 489-503
• 3 Stuyver L, De Gendt S, Van Geyt C et al.. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness.  J Gen Virol. 2000;  81(part 1) 67-74
• 4 Ganem D, Schneider R. Hepadnaviridae: the viruses and their replication. In: Knipe DM, Howley PM Fields Virology, 4th ed. Vol. 2 Philadelphia; Lippincott-Raven 2001: 2923-2970
• 5 De Meyer S, Gong Z, Suwandhi W, Van Pelt J, Soumillion A, Yap S. Organ and species specificity of hepatitis B virus (HBV) infection: a review of literature with a special reference to preferential attachment of HBV to human hepatocytes.  J Viral Hepatitis. 1997;  4 145-153
• 6 Rabe B, Vlachou A, Pante N, Helenius A, Kann M. Nuclear import of hepatitis B virus capsids and release of the viral genome.  Proc Natl Acad Sci USA. 2003;  100 9849-9854
• 7 Bock C T, Schranz P, Schroder C H, Zentgraf H. Hepatitis B virus genome is organized into nucleosomes in the nucleus of the infected cell.  Virus Genes. 1994;  8 215-229
• 8 Newbold J E, Xin H, Tencza M et al.. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minochromosomes.  J Virol. 1995;  69 3350-3357
• 9 Kann M, Gerlich W. Hepadnaviridae: structure and molecular virology. In: Zuckerman A, Thomas H Viral Hepatitis London; Churchill Livingstone 1998: 77-105
• 10 Bartenschlager R, Schaller H. Hepadnaviral assembly is initiated by polymerase binding to the encapsidation signal in the viral RNA genome.  EMBO J. 1992;  11 3413-3420
• 11 Zoulim F, Seeger C. Reverse transcription in hepatitis B viruses is primed by a tyrosine residue of the polymerase.  J Virol. 1994;  68 6-13
• 12 Will H, Reiser W, Weimer T et al.. Replication strategy of human hepatitis B virus.  J Virol. 1987;  61 904-911
• 13 Gerelsaikhan T, Tavis J E, Bruss V. Hepatitis B virus nucleocapsid envelopment does not occur without genomic DNA synthesis.  J Virol. 1996;  70 4269-4274
• 14 Scaglioni P P, Melegari M, Wands J R. Posttranscriptional regulation of hepatitis B virus replication by the precore protein.  J Virol. 1997;  71 345-353
• 15 Hadziyannis S. Hepatitis Be antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment.  Viral Hepatitis Rev. 1995;  1 7-36
• 16 Hunt C M, McGill J M, Allen M I, Condreay L D. Clinical relevance of hepatitis B viral mutations.  Hepatology. 2000;  31 1037-1044
• 17 Locarnini S, Shaw T, Dean J et al.. Cellular response to conditional expression of the hepatitis B virus precore and core proteins in cultured hepatoma (Huh-7) cells.  J Clin Virol. 2005;  32 113-121
• 18 Milich D R, Jones J E, Hughes J L, Price J, Raney A K, McLachlan A. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero?.  Proc Natl Acad Sci USA. 1990;  87 6599-6603
• 19 Bartholomeusz A, Schaefer S. Hepatitis B virus genotypes: comparison of genotyping methods.  Rev Med Virol. 2004;  14 3-16
• 20 Lok A S, Akarca U, Greene S. Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal.  Proc Natl Acad Sci USA. 1994;  91 4077-4081
• 21 Le Pogam S, Yuan T, Sahu G, Chatterjee S, Shih C. Low-level secretion of human hepatitis B virus virions caused by two independent, naturally occurring mutations (P5T and L60V) in the capsid protein.  J Virol. 2000;  74 9099-9105
• 22 Lohr H F, Gerken G, Schlicht H J, Meyer zum Buschenfeld K H, Fleischer B. Low frequency of cytotoxic liver-infiltrating T lymphocytes specific for endogenous processed surface and core proteins in chronic hepatitis B.  J Infect Dis. 1993;  68 1133-1139
• 23 Jung M, Pape G. Immunology of hepatitis B infection.  Lancet Infect Dis. 2002;  2 43-50
• 24 Gunther S, Fischer L, Pult I, Sterneck M, Will H. Naturally occurring variants of hepatitis B virus.  Adv Virus Res. 1999;  52 25-137
• 25 Akarca U S, Lok A S. Naturally occurring hepatitis B virus core gene mutations.  Hepatology. 1995;  22 50-60
• 26 Bouchard M J, Schneider R J. The enigmatic X gene of hepatitis B virus.  J Virol. 2004;  78 12725-12734
• 27 Shaw T, Locarnini S A. Preclinical aspects of lamivudine and famciclovir against hepatitis B virus.  J Viral Hepat. 1999;  6 89-106
• 28 Shaw T, Locarnini S A. Hepatic purine and pyrimidine metabolism: implications for antiviral chemotherapy of viral hepatitis.  Liver. 1995;  15 169-184
• 29 Carman W F, Zanetti A R, Karayiannis P et al.. Vaccine-induced escape mutant of hepatitis B virus.  Lancet. 1990;  336 325-329
• 30 Carman W F, Trautwein C, van Deursen F J et al.. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis.  Hepatology. 1996;  24 489-493
• 31 Shaw T, Locarnini S. Entecavir for the treatment of chronic hepatitis B.  Expert Rev Anti Infect Ther. 2004;  2 853-871
• 32 Stuyver L J, Locarnini S A, Lok A et al.. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region.  Hepatology. 2001;  33 751-757
• 33 Lai C L, Dienstag J, Schiff E et al.. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.  Clin Infect Dis. 2003;  36 687-696
• 34 Leung N. Clinical experience with lamivudine.  Semin Liver Dis. 2002;  22(suppl 1) 15-21
• 35 Angus P, Vaughan R, Xiong S et al.. Resistance to adefovir dipivoxil therapy associated with development of a novel mutation in the HBV polymerase.  Gastroenterology. 2003;  125 292-297
• 36 Tenney D J, Levine S M, Rose R E et al.. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine.  Antimicrob Agents Chemother. 2004;  48 3498-3507
• 37 Chin R, Shaw T, Torresi J et al.. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil.  Antimicrob Agents Chemother. 2001;  45 2495-2501
• 38 Ono-Nita S K, Kato N, Shiratori Y, Carrilho F J, Omata M. Novel nucleoside analogue MCC-478 (LY582563) is effective against wild-type or lamivudine-resistant hepatitis B virus.  Antimicrob Agents Chemother. 2002;  46 2602-2605
• 39 Levine S, Hernandez D, Yamanaka G et al.. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro.  Antimicrob Agents Chemother. 2002;  46 2525-2532
• 40 Delaney IV W E, Locarnini S, Shaw T. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation.  Antivir Chem Chemother. 2001;  12 1-35
• 41 Zollner B, Petersen J, Puchhammer-Stockl E et al.. Viral features of lamivudine resistant hepatitis B genotypes A and D.  Hepatology. 2004;  39 42-50
• 42 Bartholomeusz A, Tehan B G, Chalmers D K. Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations.  Antivir Ther. 2004;  9 149-160
• 43 Bartholomeusz A, Locarnini S, Ayres A et al.. Molecular modelling of hepatitis B virus polymerase and adefovir resistance identifies three clusters of mutations.  Hepatology. 2004;  40 246A
• 44 Warner N, Locarnini S, Colledge D et al.. Molecular modelling of entecavir resistant mutations in the hepatitis B virus polymerase selected during therapy.  Hepatology. 2004;  40 245A
• 45 Angus P, Locarnini S. Lamivudine-resistant hepatitis B virus and ongoing lamivudine therapy: stop the merry-go-round, it's time to get off!.  Antivir Ther. 2004;  9 145-148
• 46 Richman D D. The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B.  Hepatology. 2000;  32 866-867
• 47 Okamoto H, Imai M, Kametani M, Nakamura T, Mayumi M. Genomic heterogeneity of hepatitis B virus in a 54-year-old woman who contracted the infection through materno-fetal transmission.  Jpn J Exp Med. 1987;  57 231-236
• 48 Girones R, Miller R H. Mutation rate of the hepadnavirus genome.  Virology. 1989;  170 595-597
• 49 Nowak M A, Bonhoeffer S, Hill A M, Boehme R, Thomas H C, McDade H. Viral dynamics in hepatitis B virus infection.  Proc Natl Acad Sci USA. 1996;  93 4398-4402
• 50 Locarnini S, Hatzakis A, Heathcote J et al.. Management of antiviral resistance in patients with chronic hepatitis B.  Antivir Ther. 2004;  9 679-693
• 51 Richman D D. The implications of drug resistance for strategies of combination antiviral chemotherapy.  Antiviral Res. 1996;  29 31-33
• 52 Thibault V, Aubron-Olivier C, Agut H, Katlama C. Primary infection with a lamivudine-resistant hepatitis B virus.  AIDS. 2002;  16 131-133
• 53 Niesters H G, De Man R A, Pas S D, Fries E, Osterhaus A D. Identification of a new variant in the YMDD motif of the hepatitis B virus polymerase gene selected during lamivudine therapy.  J Med Microbiol. 2002;  51 695-699
• 54 Lok A S, Zoulim F, Locarnini S et al.. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO- LiPA HBV DR assay.  J Clin Microbiol. 2002;  40 3729-3734
• 55 Zhang Y Y, Summers J. Enrichment of a precore-minus mutant of duck hepatitis B virus in experimental mixed infections.  J Virol. 1999;  73 3616-3622
• 56 Zhang Y Y, Summers J. Low dynamic state of viral competition in a chronic avian hepadnavirus infection.  J Virol. 2000;  74 5257-5265
• 57 Doo E, Liang J T. Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection.  Gastroenterology. 2001;  120 1000-1008
• 58 Seeger C, Mason W S. Hepatitis B virus biology.  Microbiol Mol Biol Rev. 2000;  64 51-68
• 59 Locarnini S, Birch C. Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV infected patients.  J Hepatol. 1999;  30 536-550
• 60 Colgrove R, Japour A. A combinatorial ledge: reverse transcriptase fidelity, total body viral burden, and the implications of multiple-drug HIV therapy for the evolution of antiviral resistance.  Antiviral Res. 1999;  41 45-56
• 61 Shaw T, Locarnini S. Combination chemotherapy for hepatitis B virus: the path forward?.  Drugs. 2000;  60 517-531